Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
CLINICAL RESPONSE AND PARTIAL...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
Bibliographic Details
Main Authors:
Wordsworth, P
,
van der Heijde, D
,
Dijkmans, B
,
Schiff, M
,
Kivitz, A
,
de Vlam, K
,
Ballal, S
,
Kupper, H
,
Wong, R
,
Sieper, J
Format:
Conference item
Published:
2009
Holdings
Description
Similar Items
Staff View
Similar Items
Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
by: van der Heijde, D, et al.
Published: (2008)
Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
by: van der Heijde, D, et al.
Published: (2006)
Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas
by: Wordsworth, P, et al.
Published: (2008)
Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.
by: Van der Heijde, D, et al.
Published: (2005)
Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
by: Rudwaleit, M, et al.
Published: (2008)